LLY Stock Recent News

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Eli Lilly (LLY -1.24%) and Viking Therapeutics (VKTX -0.12%) have garnered considerable attention over the past year due to their solid clinical progress. However, these drugmakers have also lagged the market over the trailing-12-month period.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.

The ultimate win for investors is finding a remarkable company that is not only highly productive, but also capable of growth over many years, resulting in substantial returns for long-term shareholders.

Eli Lilly (LLY) closed at $762.18 in the latest trading session, marking a -1.23% move from the prior day.

President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.

The Investment Committee debate the latest Calls of the Day.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

The active ingredients of roughly 80% of prescription drugs sold in the U.S. are made in other countries. President Trump wants that to change.

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.